Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Assets (2016 - 2025)

Historic Current Assets for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $227.7 million.

  • Rocket Pharmaceuticals' Current Assets fell 582.16% to $227.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.7 million, marking a year-over-year decrease of 582.16%. This contributed to the annual value of $378.2 million for FY2024, which is 1.03% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Current Assets stood at $227.7 million for Q3 2025, which was down 582.16% from $277.2 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Current Assets high stood at $471.8 million for Q1 2021, and its period low was $227.7 million during Q3 2025.
  • In the last 5 years, Rocket Pharmaceuticals' Current Assets had a median value of $345.2 million in 2024 and averaged $349.3 million.
  • In the last 5 years, Rocket Pharmaceuticals' Current Assets soared by 8226.56% in 2021 and then crashed by 4590.0% in 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' Current Assets (Quarter) stood at $392.1 million in 2021, then decreased by 7.14% to $364.1 million in 2022, then grew by 3.89% to $378.2 million in 2023, then decreased by 0.01% to $378.2 million in 2024, then crashed by 39.8% to $227.7 million in 2025.
  • Its last three reported values are $227.7 million in Q3 2025, $277.2 million for Q2 2025, and $324.5 million during Q1 2025.